Metabolomics and metabolic diseases
Obesity, diabetes and cardiovascular diseases are only the tip of the iceberg of dysregulated metabolism, which is now associated not only with these “metabolic disorders” but also to other chronic diseases not traditionally considered as “metabolic” origin, such as cancer, respiratory pathologies or cognitive disorders.
Early detection for prevention
One common factor of these disorders is that they alter metabolism, which can be detected with Biomeb‘s Well B tests. Analyzing how one has these key metabolites involved in metabolic alteration, the problem can be detected at previous stages and take the necessary steps to prevent it from happening.
In fact, obesity, diabetes and cardiovascular diseases can be addressed preventively with guidelines on lifestyle that have proven to be really effective. That is why Well B aims to detect these small changes in metabolism that indicate that something is not going well and lit up the warning lights, so we can reverse the effects as soon as possible and notice a significant improvement.
Why metabolomics for metabolic diseases?
Metabolomics (the technic used to analyze these small molecule metabolites) has undergone a brisk technological progression in the past two decades. This evolution has led to its application to several metabolic diseases, and most importantly, to find biomarkers of altered metabolism before diseases show up .
Metabolomics allows us to measure a great number of small molecule metabolites in people’s blood and understand what is going on at a certain time. These clusters of small molecules are accurately chosen in Well B and used as a tool to provide a deep and dynamic view of metabolic functions in our body.
Well B has different formats, but Metabolic Health is the most complete one. It will give you information about your body, blood sugar, blood cholesterol and triglycerides, and even your cardiovascular risk. Indeed, it can give you handy tips for your everyday life to improve your health.
 Newgard CB (2017) Metabolomics and Metabolic Diseases: Where Do We Stand? Cell Metab. 25, 43–56. https://www.ncbi.nlm.nih.gov/pubmed/28094011